Korro Bio, Inc.
Korro Bio develops RNA-editing oligonucleotides using its OPERA platform to modify native mRNA transcripts for rare and prevalent diseases.
8-KAug 19Latest SEC filing, period to Aug 19
Aug 19Latest story
Sign inSign inKorro Bio develops RNA-editing oligonucleotides using its OPERA platform to modify native mRNA transcripts for rare and prevalent diseases.